高危、临床局限性前列腺癌：单药治疗是否足够？
High-risk, clinically localized prostate cancer: is monotherapy adequate?
作者信息
Katz Mark H, McKiernan James M
机构信息
Department of Urology, New York-Presbyterian Hospital/Columbia University Medical Center New York, NY.
出版信息
Rev Urol. 2007;9 Suppl 2(Suppl 2):S19-27.
High-risk, clinically localized prostate cancer represents a diverse disease entity. Patients who are considered to be at highest risk for biochemical failure after localized treatments may not be at significant risk for disea-sespecific mortality. In this review, an attempt will be made to define high-risk status and help identify patients at high risk for mortality after a diagnosis of localized prostate cancer. Subsequently, a review of monotherapy approaches as well as previously successful strategies utilizing multimodality therapy for high-risk disease will be presented. Finally, a synopsis will be given of several ongoing randomized clinical trials using the most effective systemic therapies in the adjuvant setting following thorough local treatments such as radical prostatectomy. This review will provide a glimpse into the future and describe the tools that it is hoped will improve further upon the results of surgical monotherapy for high-risk, localized prostate cancer.
高危、临床局限性前列腺癌是一种多样化的疾病实体。那些在局部治疗后被认为生化复发风险最高的患者，其疾病特异性死亡风险可能并不显著。在本综述中，将尝试定义高危状态，并帮助识别局部前列腺癌诊断后有高死亡风险的患者。随后，将介绍单药治疗方法以及先前成功用于高危疾病的多模式治疗策略。最后，将概述在根治性前列腺切除术等彻底局部治疗后，在辅助治疗中使用最有效全身治疗的几项正在进行的随机临床试验。本综述将展望未来，并描述有望进一步改善高危、局限性前列腺癌手术单药治疗结果的工具。
Zotero 插件